<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02677493</url>
  </required_header>
  <id_info>
    <org_study_id>IY_IFEZ_Q301</org_study_id>
    <nct_id>NCT02677493</nct_id>
  </id_info>
  <brief_title>Study to Evaluate the Immunogenicity and Safety of 'IL-YANG Quadrivalent Influenza Vaccine Inj.'</brief_title>
  <official_title>A Multicenter, Randomized, Double-blind, Active-controlled, Parallel Phase III Study to Investigate the Immunogenicity and Safety of 'IL-YANG Quadrivalent Influenza Vaccine Inj.' After Intramuscular Administration in Healthy Adult Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Il-Yang Pharm. Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Il-Yang Pharm. Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluates the immunogenicity and safety of 'IL-YANG Quadrivalent Influenza Vaccine&#xD;
      Inj.' in healthy male and female adults at the age of 19 or older.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In this study, only eligible subjects for the study based on the inclusion/exclusion criteria&#xD;
      will be randomized to the following stratification groups by age to receive one dose of the&#xD;
      test vaccine, comparator 1, or comparator 2.&#xD;
&#xD;
        -  Group A: healthy adults at the age of ≥ 19 and &lt; 65.&#xD;
&#xD;
        -  Group B: healthy adults at the age of ≥ 65.&#xD;
&#xD;
      During the study participation, the investigator will assess immunogenicity and safety in&#xD;
      subjects. The investigator will perform immunogenicity tests at Visits 1 and 3 (end of study&#xD;
      visit) for immunogenicity evaluation (prior to the investigational product vaccination) and&#xD;
      instruct subjects to record AEs occurring after the investigational product vaccination for&#xD;
      safety assessment.&#xD;
&#xD;
      A blood sample will be collected from a subject who is assigned a subject number. Following&#xD;
      an intramuscular injection of 0.5mL investigational product in the deltoid muscle of the&#xD;
      shoulder, the subject will have a study visit on Week 4 for blood sampling for antibody titer&#xD;
      testing. In addition, a telephone visit will be performed to assess serious AEs (SAEs) up to&#xD;
      Day 180 after vaccination.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2015</start_date>
  <completion_date type="Actual">June 2016</completion_date>
  <primary_completion_date type="Actual">January 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of Healthy Adults Aged ≥19 Years With Seroconversion</measure>
    <time_frame>Day 28</time_frame>
    <description>Seroconversion is defined as follows. (Case 1) A pre-vaccination (Day 0) HI antibody titer &lt; 1:10 and a post-vaccination (Day 28) HI antibody titer ≥ 1: 40. or (Case 2) a pre-vaccination (Day 0) HI antibody titer ≥ 1:10 and a minimum four-fold rise in post-vaccination (Day 28) HI antibody titer.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Rate of Healthy Adults Aged ≥19 Years With Seroprotection</measure>
    <time_frame>Day 28</time_frame>
    <description>Seroprotection: A post-vaccination (Day 28) HI antibody titer ≥ 1:40.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Subjects With SCR on Day 28 After Vaccination of the Investigational Product by Age Group</measure>
    <time_frame>Day 28</time_frame>
    <description>The percentage of subjects with HI antibody SCR on Day 28 after vaccination of the investigational product was calculated and its 95% two-sided CI was presented for each strain by treatment group and by age group. The immunogenicity of the test vaccine was to be demonstrated if the lower limit of the 95% two-sided CI by age group was higher than the above mentioned criteria (40% for &lt; 65 years of age, 30% for ≥ 65 years of age) in each treatment group.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of Healthy Adults Aged ≥19 ~ &lt;65 Years and ≥65 Years With Seroprotection, Respectively.</measure>
    <time_frame>Day 28</time_frame>
    <description>Seroprotection is defined as follows. subjects who have a post-vaccination (Day 28) HI antibody titer ≥ 1: 40</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Titer as Measured by HI Antibody Titer on Day 28 After Vaccination of the Investigational Product (GMTcomparator/GMTtest Vaccine).</measure>
    <time_frame>Day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference of Seroconversion Rate(SCR) of HI Antibody Titer After 28days Vaccination(SCRcomparator-SCRtest Vaccine)</measure>
    <time_frame>Day 28</time_frame>
    <description>The IL-YANG Quadrivalent Influenza Vaccine contain two types of B strain, while two kinds of Trivalent Influenza Vaccine contain each type of B strain. Primary outcome was about seroconversion and seroprotection rate of HI antibody, so each results of 3 kinds of vaccine was described. Considering the cross-reaction between two types of B strain, the analysis was designed in a way that the SCR/SPR of the B strains can be compared, respectively.&#xD;
However, secondary outcome, unlike the primary outcome, is expressed as a ratio(difference of seroconversion rate). So, the above factors were not to be consider.&#xD;
All methods of analysis are comply with the request of MFDS, and the result data that may make you confuse will be delete.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Titer as Measured by HI Antibody Titer Before (Day 0) and on Day 28 After Vaccination of the Investigational Product.</measure>
    <time_frame>Day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Ratio as Measured by HI Antibody Titer Before (Day 0) and on Day 28 After Vaccination of the Investigational Product.</measure>
    <time_frame>Day 28</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">1794</enrollment>
  <condition>Influenza</condition>
  <arm_group>
    <arm_group_label>IL-YANG Quadrivalent Influenza Vaccine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The QIV is included both B strain (Yamagata, Victoria).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>IL-YANG Flu Vaccine Prefilled Syringe</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>This TIV is included the B/Yamagata strain, and it was approved for commercial sale by MFDS.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>IL-YANG Trivalent Influenza Vaccine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>This TIV is included the B/Victoria strain.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>IL-YANG Quadrivalent Influenza Vaccine</intervention_name>
    <description>A single 0.5mL dose administrated as an intramuscular injection.</description>
    <arm_group_label>IL-YANG Quadrivalent Influenza Vaccine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>IL-YANG Flu Vaccine Prefilled Syringe</intervention_name>
    <description>A single 0.5mL dose administrated as an intramuscular injection.</description>
    <arm_group_label>IL-YANG Flu Vaccine Prefilled Syringe</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>IL-YANG Trivalent Influenza Vaccine</intervention_name>
    <description>A single 0.5mL dose administrated as an intramuscular injection.</description>
    <arm_group_label>IL-YANG Trivalent Influenza Vaccine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy men and women at the age of 19 or older.&#xD;
&#xD;
          -  Women of childbearing potential must have a negative pregnancy test (urine HCG) at the&#xD;
             screening visit.&#xD;
&#xD;
          -  Subjects who were given, and fully understood, the information about the study, and&#xD;
             have provided voluntary written informed consent to participate in the study and to&#xD;
             comply with all applicable study requirements.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subjects with known allergy to eggs, chicken, or any components of the study vaccine.&#xD;
&#xD;
          -  Subjects who had received an influenza vaccine within the last 6 months prior to study&#xD;
             entry.&#xD;
&#xD;
          -  Subjects who have immune function disorders including immunodeficiency diseases or&#xD;
             relevant family history.&#xD;
&#xD;
          -  Subjects who donated blood within 1 week prior to vaccination or plan to donate blood&#xD;
             during the period from Day 1 to Month 7 of vaccination.&#xD;
&#xD;
          -  Subjects with a history of Guillain-Barre syndrome.&#xD;
&#xD;
          -  Subjects with Down's syndrome or cytogenetic disorders.&#xD;
&#xD;
          -  Subjects who are considered by the investigator to have difficulties in study&#xD;
             participation due to severe chronic diseases (e.g., cardiovascular diseases except&#xD;
             controlled hypertension and respiratory diseases with respiratory failure, metabolic&#xD;
             diseases, renal function disorders, hemoglobinopathy, etc.).&#xD;
&#xD;
          -  Subjects with hemophilia or coagulation disorder, who are at increased risk of serious&#xD;
             bleeding during intramuscular injection.&#xD;
&#xD;
          -  Subjects who had an acute fever with body temperature &gt; 38.0 ºC within 72 hours prior&#xD;
             to administration of the study vaccine.&#xD;
&#xD;
          -  Subjects who had received another vaccine within 28 days before administration of the&#xD;
             study vaccine or are planning to receive another vaccine during the study.&#xD;
&#xD;
          -  Subjects who had received immunosuppressants or immune modifying drugs within 3 months&#xD;
             prior to the investigational product vaccination.&#xD;
&#xD;
               1. Azathioprine, cyclosporin, interferon, G-CSF, tacrolimus, everolimus, sirolimus,&#xD;
                  etc.&#xD;
&#xD;
               2. High dose corticosteroids (a subject taking high doses, which is defined as&#xD;
                  2mg/kg/day or higher of prednisolone administered for longer than 14 consecutive&#xD;
                  days, is not eligible for this study. The use of inhaled, nasal and topical&#xD;
                  corticosteroids is allowed, regardless of doses).&#xD;
&#xD;
          -  Subjects who had previously received immunoglobulin or blood-derived products within&#xD;
             the last 3 months prior to administration of the study vaccine, or are scheduled to&#xD;
             receive a treatment with blood-derived products during the study.&#xD;
&#xD;
          -  Subjects who had participated in another clinical trial within the 30 days before&#xD;
             administration of the study vaccine.&#xD;
&#xD;
          -  Female subjects of childbearing potential who do not agree to use an acceptable method&#xD;
             of birth control* for this study during the study period.&#xD;
&#xD;
               -  Medically acceptable methods of birth control: condom, injectable or implantable&#xD;
                  contraceptives, intrauterine device, or oral contraceptives, etc.&#xD;
&#xD;
          -  Subjects with other clinically significant medical or psychiatric illness who in the&#xD;
             investigator's opinion, are not be suitable for the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>February 3, 2016</study_first_submitted>
  <study_first_submitted_qc>February 8, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 9, 2016</study_first_posted>
  <results_first_submitted>June 21, 2016</results_first_submitted>
  <results_first_submitted_qc>December 13, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">February 6, 2017</results_first_posted>
  <last_update_submitted>July 12, 2020</last_update_submitted>
  <last_update_submitted_qc>July 12, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 30, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Influenza, Human</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>IL-YANG Quadrivalent Influenza Vaccine</title>
          <description>The QIV is included both B strain (Yamagata, Victoria).&#xD;
IL-YANG Quadrivalent Influenza Vaccine: A single 0.5mL dose administrated as an intramuscular injection.</description>
        </group>
        <group group_id="P2">
          <title>IL-YANG Flu Vaccine Prefilled Syringe</title>
          <description>This TIV is included the B/Yamagata strain, and it was approved for commercial sale by MFDS.&#xD;
IL-YANG Flu Vaccine Prefilled Syringe: A single 0.5mL dose administrated as an intramuscular injection.</description>
        </group>
        <group group_id="P3">
          <title>IL-YANG Trivalent Influenza Vaccine</title>
          <description>This TIV is included the B/Victoria strain.&#xD;
IL-YANG Trivalent Influenza Vaccine: A single 0.5mL dose administrated as an intramuscular injection.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="1197"/>
                <participants group_id="P2" count="298"/>
                <participants group_id="P3" count="299"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1186"/>
                <participants group_id="P2" count="296"/>
                <participants group_id="P3" count="296"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>IL-YANG Quadrivalent Influenza Vaccine</title>
          <description>The QIV is included both B strain (Yamagata, Victoria).&#xD;
IL-YANG Quadrivalent Influenza Vaccine: A single 0.5mL dose administrated as an intramuscular injection.</description>
        </group>
        <group group_id="B2">
          <title>IL-YANG Flu Vaccine Prefilled Syringe</title>
          <description>This TIV is included the B/Yamagata strain, and it was approved for commercial sale by MFDS.&#xD;
IL-YANG Flu Vaccine Prefilled Syringe: A single 0.5mL dose administrated as an intramuscular injection.</description>
        </group>
        <group group_id="B3">
          <title>IL-YANG Trivalent Influenza Vaccine</title>
          <description>This TIV is included the B/Victoria strain.&#xD;
IL-YANG Trivalent Influenza Vaccine: A single 0.5mL dose administrated as an intramuscular injection.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="1197"/>
            <count group_id="B2" value="298"/>
            <count group_id="B3" value="299"/>
            <count group_id="B4" value="1794"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1015"/>
                    <measurement group_id="B2" value="254"/>
                    <measurement group_id="B3" value="253"/>
                    <measurement group_id="B4" value="1522"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="182"/>
                    <measurement group_id="B2" value="44"/>
                    <measurement group_id="B3" value="46"/>
                    <measurement group_id="B4" value="272"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="44.7" spread="14.5"/>
                    <measurement group_id="B2" value="44.5" spread="14.7"/>
                    <measurement group_id="B3" value="45.7" spread="14.6"/>
                    <measurement group_id="B4" value="44.8" spread="14.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="812"/>
                    <measurement group_id="B2" value="208"/>
                    <measurement group_id="B3" value="204"/>
                    <measurement group_id="B4" value="1224"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="385"/>
                    <measurement group_id="B2" value="90"/>
                    <measurement group_id="B3" value="95"/>
                    <measurement group_id="B4" value="570"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Rate of Healthy Adults Aged ≥19 Years With Seroconversion</title>
        <description>Seroconversion is defined as follows. (Case 1) A pre-vaccination (Day 0) HI antibody titer &lt; 1:10 and a post-vaccination (Day 28) HI antibody titer ≥ 1: 40. or (Case 2) a pre-vaccination (Day 0) HI antibody titer ≥ 1:10 and a minimum four-fold rise in post-vaccination (Day 28) HI antibody titer.</description>
        <time_frame>Day 28</time_frame>
        <population>The immunogenicity data obtained from the study subjects were analyzed primarily in the Per Protocol Set that was consists of subjects who had at least one dose of the investigational product and from whom post-treatment primary efficacy endpoint data, and have completed the study up to Visit 3 without a major protocol violation.</population>
        <group_list>
          <group group_id="O1">
            <title>IL-YANG Quadrivalent Influenza Vaccine</title>
            <description>The QIV is included both B strain (Yamagata, Victoria).&#xD;
IL-YANG Quadrivalent Influenza Vaccine: A single 0.5mL dose administrated as an intramuscular injection.</description>
          </group>
          <group group_id="O2">
            <title>IL-YANG Flu Vaccine Prefilled Syringe</title>
            <description>This TIV is included the B/Yamagata strain, and it was approved for commercial sale by MFDS.&#xD;
IL-YANG Flu Vaccine Prefilled Syringe: A single 0.5mL dose administrated as an intramuscular injection.</description>
          </group>
          <group group_id="O3">
            <title>IL-YANG Trivalent Influenza Vaccine</title>
            <description>This TIV is included the B/Victoria strain.&#xD;
IL-YANG Trivalent Influenza Vaccine: A single 0.5mL dose administrated as an intramuscular injection.</description>
          </group>
        </group_list>
        <measure>
          <title>Rate of Healthy Adults Aged ≥19 Years With Seroconversion</title>
          <description>Seroconversion is defined as follows. (Case 1) A pre-vaccination (Day 0) HI antibody titer &lt; 1:10 and a post-vaccination (Day 28) HI antibody titer ≥ 1: 40. or (Case 2) a pre-vaccination (Day 0) HI antibody titer ≥ 1:10 and a minimum four-fold rise in post-vaccination (Day 28) HI antibody titer.</description>
          <population>The immunogenicity data obtained from the study subjects were analyzed primarily in the Per Protocol Set that was consists of subjects who had at least one dose of the investigational product and from whom post-treatment primary efficacy endpoint data, and have completed the study up to Visit 3 without a major protocol violation.</population>
          <units>percentage of subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1175"/>
                <count group_id="O2" value="293"/>
                <count group_id="O3" value="294"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>A/H1N1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47.7" lower_limit="44.9" upper_limit="50.6"/>
                    <measurement group_id="O2" value="49.5" lower_limit="43.6" upper_limit="55.4"/>
                    <measurement group_id="O3" value="49.0" lower_limit="43.1" upper_limit="54.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H3N2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="78.7" lower_limit="76.3" upper_limit="81.0"/>
                    <measurement group_id="O2" value="81.6" lower_limit="76.6" upper_limit="85.8"/>
                    <measurement group_id="O3" value="77.9" lower_limit="72.7" upper_limit="82.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Yamagata</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51.8" lower_limit="48.9" upper_limit="54.7"/>
                    <measurement group_id="O2" value="54.9" lower_limit="49.1" upper_limit="60.7"/>
                    <measurement group_id="O3" value="23.1" lower_limit="18.4" upper_limit="28.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Victoria</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47.7" lower_limit="44.9" upper_limit="50.6"/>
                    <measurement group_id="O2" value="24.2" lower_limit="19.4" upper_limit="29.6"/>
                    <measurement group_id="O3" value="54.8" lower_limit="48.9" upper_limit="60.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Rate of Healthy Adults Aged ≥19 Years With Seroprotection</title>
        <description>Seroprotection: A post-vaccination (Day 28) HI antibody titer ≥ 1:40.</description>
        <time_frame>Day 28</time_frame>
        <population>The immunogenicity data obtained from the study subjects were analyzed primarily in the Per Protocol Set that was consists of subjects who had at least one dose of the investigational product and from whom post-treatment primary efficacy endpoint data, and have completed the study up to Visit 3 without a major protocol violation.</population>
        <group_list>
          <group group_id="O1">
            <title>IL-YANG Quadrivalent Influenza Vaccine</title>
            <description>The QIV is included both B strain (Yamagata, Victoria).&#xD;
IL-YANG Quadrivalent Influenza Vaccine: A single 0.5mL dose administrated as an intramuscular injection.</description>
          </group>
          <group group_id="O2">
            <title>IL-YANG Flu Vaccine Prefilled Syringe</title>
            <description>This TIV is included the B/Yamagata strain, and it was approved for commercial sale by MFDS.&#xD;
IL-YANG Flu Vaccine Prefilled Syringe: A single 0.5mL dose administrated as an intramuscular injection.</description>
          </group>
          <group group_id="O3">
            <title>IL-YANG Trivalent Influenza Vaccine</title>
            <description>This TIV is included the B/Victoria strain.&#xD;
IL-YANG Trivalent Influenza Vaccine: A single 0.5mL dose administrated as an intramuscular injection.</description>
          </group>
        </group_list>
        <measure>
          <title>Rate of Healthy Adults Aged ≥19 Years With Seroprotection</title>
          <description>Seroprotection: A post-vaccination (Day 28) HI antibody titer ≥ 1:40.</description>
          <population>The immunogenicity data obtained from the study subjects were analyzed primarily in the Per Protocol Set that was consists of subjects who had at least one dose of the investigational product and from whom post-treatment primary efficacy endpoint data, and have completed the study up to Visit 3 without a major protocol violation.</population>
          <units>percentage of subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1175"/>
                <count group_id="O2" value="293"/>
                <count group_id="O3" value="294"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>A/H1N1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="88.2" lower_limit="86.2" upper_limit="90.0"/>
                    <measurement group_id="O2" value="89.4" lower_limit="85.3" upper_limit="92.7"/>
                    <measurement group_id="O3" value="87.1" lower_limit="82.7" upper_limit="90.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H3N2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90.0" lower_limit="88.1" upper_limit="91.6"/>
                    <measurement group_id="O2" value="92.5" lower_limit="88.9" upper_limit="95.2"/>
                    <measurement group_id="O3" value="89.5" lower_limit="85.4" upper_limit="92.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Yamagata</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="86.3" lower_limit="84.2" upper_limit="88.2"/>
                    <measurement group_id="O2" value="88.4" lower_limit="84.2" upper_limit="91.8"/>
                    <measurement group_id="O3" value="64.6" lower_limit="58.9" upper_limit="70.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Victoria</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="84.9" lower_limit="82.8" upper_limit="86.9"/>
                    <measurement group_id="O2" value="69.3" lower_limit="63.7" upper_limit="74.5"/>
                    <measurement group_id="O3" value="85.7" lower_limit="81.2" upper_limit="89.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>To evaluate if the seroconversion (SCR) and seroprotection (SPR) rates on Day 28 after vaccination of IL-YANG Quadrivalent Influenza Vaccine Inj. meet the following criteria in all age groups of healthy male and female adults at the age of 19 or older.</groups_desc>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>All statistical significance testing was performed at a two-sided significance level (α) of 5%.&#xD;
Exceptionally, non-inferiority was tested at a one-sided CI of 97.5%.</non_inferiority_desc>
            <p_value>0.09135</p_value>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Subjects With SCR on Day 28 After Vaccination of the Investigational Product by Age Group</title>
        <description>The percentage of subjects with HI antibody SCR on Day 28 after vaccination of the investigational product was calculated and its 95% two-sided CI was presented for each strain by treatment group and by age group. The immunogenicity of the test vaccine was to be demonstrated if the lower limit of the 95% two-sided CI by age group was higher than the above mentioned criteria (40% for &lt; 65 years of age, 30% for ≥ 65 years of age) in each treatment group.</description>
        <time_frame>Day 28</time_frame>
        <population>Rate of healthy adults aged ≥19 ~ &lt;65 years</population>
        <group_list>
          <group group_id="O1">
            <title>IL-YANG Quadrivalent Influenza Vaccine</title>
            <description>The QIV is included both B strain (Yamagata, Victoria).&#xD;
IL-YANG Quadrivalent Influenza Vaccine: A single 0.5mL dose administrated as an intramuscular injection.</description>
          </group>
          <group group_id="O2">
            <title>IL-YANG Flu Vaccine Prefilled Syringe</title>
            <description>This TIV is included the B/Yamagata strain, and it was approved for commercial sale by MFDS.&#xD;
IL-YANG Flu Vaccine Prefilled Syringe: A single 0.5mL dose administrated as an intramuscular injection.</description>
          </group>
          <group group_id="O3">
            <title>IL-YANG Trivalent Influenza Vaccine</title>
            <description>This TIV is included the B/Victoria strain.&#xD;
IL-YANG Trivalent Influenza Vaccine: A single 0.5mL dose administrated as an intramuscular injection.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Subjects With SCR on Day 28 After Vaccination of the Investigational Product by Age Group</title>
          <description>The percentage of subjects with HI antibody SCR on Day 28 after vaccination of the investigational product was calculated and its 95% two-sided CI was presented for each strain by treatment group and by age group. The immunogenicity of the test vaccine was to be demonstrated if the lower limit of the 95% two-sided CI by age group was higher than the above mentioned criteria (40% for &lt; 65 years of age, 30% for ≥ 65 years of age) in each treatment group.</description>
          <population>Rate of healthy adults aged ≥19 ~ &lt;65 years</population>
          <units>percentage of participants</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="996"/>
                <count group_id="O2" value="251"/>
                <count group_id="O3" value="249"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Strain H1N1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48.7" lower_limit="45.5" upper_limit="51.8"/>
                    <measurement group_id="O2" value="51.8" lower_limit="45.4" upper_limit="58.1"/>
                    <measurement group_id="O3" value="51.8" lower_limit="45.4" upper_limit="58.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Strain H3N2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80.3" lower_limit="77.7" upper_limit="82.7"/>
                    <measurement group_id="O2" value="83.3" lower_limit="78.1" upper_limit="87.7"/>
                    <measurement group_id="O3" value="78.7" lower_limit="73.1" upper_limit="83.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Strain B Yamagata</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52.3" lower_limit="49.2" upper_limit="55.5"/>
                    <measurement group_id="O2" value="54.6" lower_limit="48.2" upper_limit="60.9"/>
                    <measurement group_id="O3" value="24.5" lower_limit="19.3" upper_limit="30.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Strain B Victoria</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48.3" lower_limit="45.1" upper_limit="51.4"/>
                    <measurement group_id="O2" value="27.5" lower_limit="22.1" upper_limit="33.5"/>
                    <measurement group_id="O3" value="56.6" lower_limit="50.2" upper_limit="62.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Rate of Healthy Adults Aged ≥19 ~ &lt;65 Years and ≥65 Years With Seroprotection, Respectively.</title>
        <description>Seroprotection is defined as follows. subjects who have a post-vaccination (Day 28) HI antibody titer ≥ 1: 40</description>
        <time_frame>Day 28</time_frame>
        <population>Rate of healthy adults aged ≥65 years</population>
        <group_list>
          <group group_id="O1">
            <title>IL-YANG Quadrivalent Influenza Vaccine</title>
            <description>The QIV is included both B strain (Yamagata, Victoria).&#xD;
IL-YANG Quadrivalent Influenza Vaccine: A single 0.5mL dose administrated as an intramuscular injection.</description>
          </group>
          <group group_id="O2">
            <title>IL-YANG Flu Vaccine Prefilled Syringe</title>
            <description>This TIV is included the B/Yamagata strain, and it was approved for commercial sale by MFDS.&#xD;
IL-YANG Flu Vaccine Prefilled Syringe: A single 0.5mL dose administrated as an intramuscular injection.</description>
          </group>
          <group group_id="O3">
            <title>IL-YANG Trivalent Influenza Vaccine</title>
            <description>This TIV is included the B/Victoria strain.&#xD;
IL-YANG Trivalent Influenza Vaccine: A single 0.5mL dose administrated as an intramuscular injection.</description>
          </group>
        </group_list>
        <measure>
          <title>Rate of Healthy Adults Aged ≥19 ~ &lt;65 Years and ≥65 Years With Seroprotection, Respectively.</title>
          <description>Seroprotection is defined as follows. subjects who have a post-vaccination (Day 28) HI antibody titer ≥ 1: 40</description>
          <population>Rate of healthy adults aged ≥65 years</population>
          <units>percentage of participants</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="179"/>
                <count group_id="O2" value="42"/>
                <count group_id="O3" value="45"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Strain H1N1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42.5" lower_limit="35.1" upper_limit="50.1"/>
                    <measurement group_id="O2" value="35.7" lower_limit="21.6" upper_limit="52.0"/>
                    <measurement group_id="O3" value="33.3" lower_limit="20.0" upper_limit="49.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Strain H3N2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69.8" lower_limit="62.5" upper_limit="76.5"/>
                    <measurement group_id="O2" value="71.4" lower_limit="55.4" upper_limit="84.3"/>
                    <measurement group_id="O3" value="73.3" lower_limit="58.1" upper_limit="85.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Strain B Yamagata</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49.2" lower_limit="41.6" upper_limit="56.7"/>
                    <measurement group_id="O2" value="57.1" lower_limit="41.0" upper_limit="72.3"/>
                    <measurement group_id="O3" value="15.6" lower_limit="6.5" upper_limit="29.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Strain B Victoria</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44.7" lower_limit="37.3" upper_limit="52.3"/>
                    <measurement group_id="O2" value="4.8" lower_limit="0.6" upper_limit="16.2"/>
                    <measurement group_id="O3" value="44.4" lower_limit="29.6" upper_limit="60.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Geometric Mean Titer as Measured by HI Antibody Titer on Day 28 After Vaccination of the Investigational Product (GMTcomparator/GMTtest Vaccine).</title>
        <time_frame>Day 28</time_frame>
        <group_list>
          <group group_id="O1">
            <title>IL-YANG Quadrivalent Influenza Vaccine</title>
            <description>The QIV is included both B strain (Yamagata, Victoria).&#xD;
IL-YANG Quadrivalent Influenza Vaccine: A single 0.5mL dose administrated as an intramuscular injection.</description>
          </group>
          <group group_id="O2">
            <title>IL-YANG Flu Vaccine Prefilled Syringe.IL-YANG Trivalent Influe</title>
            <description>This TIV is included the B/Yamagata strain, and it was approved for commercial sale by MFDS.&#xD;
IL-YANG Flu Vaccine Prefilled Syringe: A single 0.5mL dose administrated as an intramuscular injection.</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Titer as Measured by HI Antibody Titer on Day 28 After Vaccination of the Investigational Product (GMTcomparator/GMTtest Vaccine).</title>
          <units>Titer</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1175"/>
                <count group_id="O2" value="587"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Strain H1N1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="82.2" lower_limit="77.8" upper_limit="86.9"/>
                    <measurement group_id="O2" value="85.1" lower_limit="78.4" upper_limit="92.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Strain H3N2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="127.6" lower_limit="119.5" upper_limit="136.2"/>
                    <measurement group_id="O2" value="130.6" lower_limit="119.1" upper_limit="143.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Strain B Yamagata</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74.3" lower_limit="70.5" upper_limit="78.3"/>
                    <measurement group_id="O2" value="75.9" lower_limit="67.9" upper_limit="85.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Strain B Victoria</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60.1" lower_limit="57.5" upper_limit="62.9"/>
                    <measurement group_id="O2" value="62.0" lower_limit="56.5" upper_limit="68.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Difference of Seroconversion Rate(SCR) of HI Antibody Titer After 28days Vaccination(SCRcomparator-SCRtest Vaccine)</title>
        <description>The IL-YANG Quadrivalent Influenza Vaccine contain two types of B strain, while two kinds of Trivalent Influenza Vaccine contain each type of B strain. Primary outcome was about seroconversion and seroprotection rate of HI antibody, so each results of 3 kinds of vaccine was described. Considering the cross-reaction between two types of B strain, the analysis was designed in a way that the SCR/SPR of the B strains can be compared, respectively.&#xD;
However, secondary outcome, unlike the primary outcome, is expressed as a ratio(difference of seroconversion rate). So, the above factors were not to be consider.&#xD;
All methods of analysis are comply with the request of MFDS, and the result data that may make you confuse will be delete.</description>
        <time_frame>Day 28</time_frame>
        <population>Please see &quot;Outcome Measure Description&quot; and &quot;Arm/Group Description&quot;above.</population>
        <group_list>
          <group group_id="O1">
            <title>IL-YANG Trivalent Vaccine (Combined)</title>
            <description>This Arm/Group is combination of &quot;IL-YANG Flu Vaccine Prefilled Syringe&quot; and &quot;IL-YANG Trivalent Influenza Vaccine&quot; Arm/Group.&#xD;
-Reason that the two arms were combined IL-YANG Flu Vaccine Prefilled Syringe: contains H1N1, H3N2 and Yamagata strain. IL-YANG Trivalent Influenza Vaccine: includes H1N1, H3N2 and Victoria strain.&#xD;
-&gt; To be used the above two trivalent vaccines as a control for the Quadrivalent vaccine, the results of seroconversion rate of above two trivalent vaccine was combined.</description>
          </group>
          <group group_id="O2">
            <title>IL-YANG Quadrivalent Influenza Vaccine</title>
            <description>The QIV is included both B strain (Yamagata, Victoria).&#xD;
IL-YANG Quadrivalent Influenza Vaccine: A single 0.5mL dose administrated as an intramuscular injection.</description>
          </group>
        </group_list>
        <measure>
          <title>Difference of Seroconversion Rate(SCR) of HI Antibody Titer After 28days Vaccination(SCRcomparator-SCRtest Vaccine)</title>
          <description>The IL-YANG Quadrivalent Influenza Vaccine contain two types of B strain, while two kinds of Trivalent Influenza Vaccine contain each type of B strain. Primary outcome was about seroconversion and seroprotection rate of HI antibody, so each results of 3 kinds of vaccine was described. Considering the cross-reaction between two types of B strain, the analysis was designed in a way that the SCR/SPR of the B strains can be compared, respectively.&#xD;
However, secondary outcome, unlike the primary outcome, is expressed as a ratio(difference of seroconversion rate). So, the above factors were not to be consider.&#xD;
All methods of analysis are comply with the request of MFDS, and the result data that may make you confuse will be delete.</description>
          <population>Please see &quot;Outcome Measure Description&quot; and &quot;Arm/Group Description&quot;above.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="587"/>
                <count group_id="O2" value="1175"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Strain H1N1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49.2" lower_limit="45.1" upper_limit="53.4"/>
                    <measurement group_id="O2" value="47.7" lower_limit="44.9" upper_limit="50.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Strain H3N2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="79.7" lower_limit="76.2" upper_limit="82.9"/>
                    <measurement group_id="O2" value="78.7" lower_limit="76.3" upper_limit="81.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Strain B Yamagata</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54.9" lower_limit="49.1" upper_limit="60.7"/>
                    <measurement group_id="O2" value="51.8" lower_limit="48.9" upper_limit="54.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Strain B Victoria</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54.8" lower_limit="48.9" upper_limit="60.5"/>
                    <measurement group_id="O2" value="47.7" lower_limit="44.9" upper_limit="50.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Geometric Mean Titer as Measured by HI Antibody Titer Before (Day 0) and on Day 28 After Vaccination of the Investigational Product.</title>
        <time_frame>Day 28</time_frame>
        <group_list>
          <group group_id="O1">
            <title>IL-YANG Quadrivalent Influenza Vaccine</title>
            <description>The QIV is included both B strain (Yamagata, Victoria).&#xD;
IL-YANG Quadrivalent Influenza Vaccine: A single 0.5mL dose administrated as an intramuscular injection.</description>
          </group>
          <group group_id="O2">
            <title>IL-YANG Flu Vaccine Prefilled Syringe</title>
            <description>This TIV is included the B/Yamagata strain, and it was approved for commercial sale by MFDS.&#xD;
IL-YANG Flu Vaccine Prefilled Syringe: A single 0.5mL dose administrated as an intramuscular injection.</description>
          </group>
          <group group_id="O3">
            <title>IL-YANG Trivalent Influenza Vaccine</title>
            <description>This TIV is included the B/Victoria strain.&#xD;
IL-YANG Trivalent Influenza Vaccine: A single 0.5mL dose administrated as an intramuscular injection.</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Titer as Measured by HI Antibody Titer Before (Day 0) and on Day 28 After Vaccination of the Investigational Product.</title>
          <units>Titer</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1175"/>
                <count group_id="O2" value="293"/>
                <count group_id="O3" value="294"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Strain H1N1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="82.2" lower_limit="77.8" upper_limit="86.9"/>
                    <measurement group_id="O2" value="89.8" lower_limit="79.7" upper_limit="101.3"/>
                    <measurement group_id="O3" value="80.6" lower_limit="72.1" upper_limit="90.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Strain H3N2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="127.6" lower_limit="119.5" upper_limit="136.2"/>
                    <measurement group_id="O2" value="135.6" lower_limit="118.7" upper_limit="154.9"/>
                    <measurement group_id="O3" value="125.8" lower_limit="110.7" upper_limit="143.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Strain B Yamagata</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74.3" lower_limit="70.5" upper_limit="78.3"/>
                    <measurement group_id="O2" value="75.9" lower_limit="67.9" upper_limit="85.0"/>
                    <measurement group_id="O3" value="44.0" lower_limit="39.6" upper_limit="48.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Strain B Victoria</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60.1" lower_limit="57.5" upper_limit="62.9"/>
                    <measurement group_id="O2" value="41.2" lower_limit="37.6" upper_limit="45.2"/>
                    <measurement group_id="O3" value="62.0" lower_limit="56.5" upper_limit="68.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Geometric Mean Ratio as Measured by HI Antibody Titer Before (Day 0) and on Day 28 After Vaccination of the Investigational Product.</title>
        <time_frame>Day 28</time_frame>
        <group_list>
          <group group_id="O1">
            <title>IL-YANG Quadrivalent Influenza Vaccine</title>
            <description>The QIV is included both B strain (Yamagata, Victoria).&#xD;
IL-YANG Quadrivalent Influenza Vaccine: A single 0.5mL dose administrated as an intramuscular injection.</description>
          </group>
          <group group_id="O2">
            <title>IL-YANG Flu Vaccine Prefilled Syringe</title>
            <description>This TIV is included the B/Yamagata strain, and it was approved for commercial sale by MFDS.&#xD;
IL-YANG Flu Vaccine Prefilled Syringe: A single 0.5mL dose administrated as an intramuscular injection.</description>
          </group>
          <group group_id="O3">
            <title>IL-YANG Trivalent Influenza Vaccine</title>
            <description>This TIV is included the B/Victoria strain.&#xD;
IL-YANG Trivalent Influenza Vaccine: A single 0.5mL dose administrated as an intramuscular injection.</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Ratio as Measured by HI Antibody Titer Before (Day 0) and on Day 28 After Vaccination of the Investigational Product.</title>
          <units>Ratio of GMT titer</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1175"/>
                <count group_id="O2" value="293"/>
                <count group_id="O3" value="294"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Strain H1N1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.9" lower_limit="3.6" upper_limit="4.2"/>
                    <measurement group_id="O2" value="4.1" lower_limit="3.5" upper_limit="4.8"/>
                    <measurement group_id="O3" value="3.7" lower_limit="3.1" upper_limit="4.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Strain H3N2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.5" lower_limit="8.8" upper_limit="10.2"/>
                    <measurement group_id="O2" value="10.9" lower_limit="9.5" upper_limit="12.6"/>
                    <measurement group_id="O3" value="9.8" lower_limit="8.5" upper_limit="11.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Strain B Yamagata</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.3" lower_limit="3.1" upper_limit="3.5"/>
                    <measurement group_id="O2" value="3.5" lower_limit="3.1" upper_limit="3.9"/>
                    <measurement group_id="O3" value="2.0" lower_limit="1.8" upper_limit="2.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Strain B Victoria</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.9" lower_limit="2.8" upper_limit="3.1"/>
                    <measurement group_id="O2" value="2.1" lower_limit="1.9" upper_limit="2.2"/>
                    <measurement group_id="O3" value="3.0" lower_limit="2.7" upper_limit="3.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>Safety set consists of all randomized subjects who had at least one dose of the investigational product. A subject who was randomized in this study but was withdrawn prior to vaccination of the investigational product was excluded from the safety set. There was 3-subject withdrawn prior to vaccination from 1197 enrolled subjects.</desc>
      <group_list>
        <group group_id="E1">
          <title>IL-YANG Quadrivalent Influenza Vaccine</title>
          <description>The QIV is included both B strain (Yamagata, Victoria).&#xD;
IL-YANG Quadrivalent Influenza Vaccine: A single 0.5mL dose administrated as an intramuscular injection.</description>
        </group>
        <group group_id="E2">
          <title>IL-YANG Flu Vaccine Prefilled Syringe</title>
          <description>This TIV is included the B/Yamagata strain, and it was approved for commercial sale by MFDS.&#xD;
IL-YANG Flu Vaccine Prefilled Syringe: A single 0.5mL dose administrated as an intramuscular injection.</description>
        </group>
        <group group_id="E3">
          <title>IL-YANG Trivalent Influenza Vaccine</title>
          <description>This TIV is included the B/Victoria strain.&#xD;
IL-YANG Trivalent Influenza Vaccine: A single 0.5mL dose administrated as an intramuscular injection.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1194"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="298"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="299"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Anal fistula</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1194"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="298"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="299"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1194"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="298"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="299"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Vascular headache</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1194"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="298"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="299"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1194"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="298"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="299"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Clinical Research Manager</name_or_title>
      <organization>IL-YANG PHARM.</organization>
      <phone>+82-70-7165-7316 ext 7316</phone>
      <email>hlpark@ilyang.co.kr</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

